Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 0.55 |
| ▸ | MMP1 | P03956 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 9/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764610 | 0.88 | MMP13 (0.70) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL6764875 | 0.88 | MMP13 (0.70) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL6764872 | 0.88 | MMP13 (0.70) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL4652477 | 0.85 | MMP13 (0.56) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL6764587 | 0.82 | MMP1 (0.57) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL8441721 | 0.82 | MMP1 (0.57) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL8028467 | 0.76 | MMP2 (0.80) | MMP2MMP9 | |
| SCHEMBL7684276 | 0.75 | MMP1 (0.64) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL1796948 | 0.73 | MMP1 (0.60) | MMP13MMP1MMP2ADAM17MMP9 | |
| SCHEMBL1796951 | 0.73 | MMP1 (0.60) | MMP13MMP1MMP2ADAM17MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966438-A1 | N-HYDROXY-BETA-SULFONYL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | PFIZER INC. (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0930067-A2 | MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS | Pfizer Products Inc. (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998034915-A1 | N-HYDROXY-BETA-SULFONYL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | claimed |
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-0966438-A1 | N-HYDROXY-BETA-SULFONYL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | PFIZER INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0930067-A2 | MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS | Pfizer Products Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998034915-A1 | N-HYDROXY-BETA-SULFONYL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | MMP13 203/4885MMP1 397/4885MMP2 1163/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | MMP13 789/4885MMP1 1271/4885MMP2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.